Expression Pathology, MD Anderson Evaluating Technology for Lung Cancer Therapy Selection | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.

Specifically, the deal is for the evaluation of the technology for matching the most appropriate targeted therapies with lung cancer patients.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.